Aurobindo Pharma gets 8 observations from USFDA for two units in Hyderabad

06 Nov 2019 Evaluate

The United States Food and Drug Administration (USFDA) has issued four observations each for Aurobindo Pharma’s two units in Hyderabad after inspecting the sites in October. The USFDA inspected active pharmaceutical ingredients (API) manufacturing facility (Unit V) at Pashamylaram and API manufacturing facility (Unit VIII) at Gaddapotharam in Hyderabad between October 21, 2019 and October 28, 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1114.90 5.10 (0.46%)
18-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.80
Dr. Reddys Lab 5959.10
Cipla 1352.95
Zydus Lifesciences 934.50
Lupin 1599.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.